Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jan 19, 2018
Clinical News

Albireo gets $55M for elobixibat approval in Japan

BioCentury | Feb 8, 2017
Clinical News

Elobixibat regulatory update

BioCentury | Oct 10, 2016
Clinical News

Elobixibat: Phase III data

BioCentury | Nov 23, 2015
Clinical News

Elobixibat: Phase III started

BioCentury | Jun 20, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

BioCentury | May 13, 2013
Clinical News

Elobixibat: Phase III started

BioCentury | Apr 9, 2012
Company News

Albireo, Ajinomoto deal

BioCentury | May 23, 2011
Clinical News

A3309: Phase IIb data

Items per page:
1 - 10 of 17